JCO Global Oncology最新文献

{"title":"Assessing Breast Cancer Diagnosis and Management in Ghana per the Global Breast Cancer Initiative Key Performance Indicators.","authors":"Samuel Mensah, Ishmael Kyei, Kwabena Agbedinu, Joshua Shiako, Dennis Afful Yorke, Adam Gyedu","doi":"10.1200/GO-24-00653","DOIUrl":"https://doi.org/10.1200/GO-24-00653","url":null,"abstract":"<p><strong>Purpose: </strong>The WHO's Global Breast Cancer Initiative (GBCI) described three key performance indicators (KPIs) to reduce breast cancer deaths worldwide. We assessed the management of breast cancer in Ghana against the GBCI KPIs to inform necessary steps for system-wide improvement.</p><p><strong>Methods: </strong>We reviewed patients diagnosed with breast cancer in 2021 calendar year at Ghana's second largest tertiary hospital. Relevant data were extracted from the electronic medical records to determine the stage of breast cancer at diagnosis, duration to confirm diagnosis from initial presentation, and proportion of patients completing recommended treatment without abandonment. Data were presented as descriptive statistics and compared with GBCI KPI benchmarks.</p><p><strong>Results: </strong>Of 319 patients undergoing biopsy of suspicious breast lesions, 243 were diagnosed with breast cancer. Most (98.7%) were female, with a median age of 49 years and median symptom duration of 24 weeks. Diagnosis was confirmed for all patients within 31 days of initial presentation. Only 22 of 214 patients (10.3%) undergoing staging were diagnosed as early breast cancer (stage I or II), 50% at stage III, and 39.3% at stage IV. Forty-five of 139 patients (32.4%) initiating recommended treatment completed without abandonment, and 45 of 243 patients (18.5%) with a confirmed breast cancer completed recommended treatment without abandonment.</p><p><strong>Conclusion: </strong>Ghana met the GBCI KPI for timely diagnosis (<60 days of presentation) but fell short in early detection (≥60% early breast cancer) and treatment completion without abandonment (>80%). Our findings provide baseline data for planning system-wide improvements toward the GBCI's goal of reducing breast cancer mortality by 2.5% annually.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400653"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review.","authors":"Héctor A Vaquera-Alfaro, José Emiliano Montelongo-Cepeda, Antonio Vega-Mateos, Anahí Morales-Pedraza, Haydeé Verduzco-Aguirre, David Gómez Almaguer, Luis Villela, Perla R Colunga-Pedraza","doi":"10.1200/GO-24-00538","DOIUrl":"10.1200/GO-24-00538","url":null,"abstract":"<p><strong>Purpose: </strong>Blockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reductions on the basis of pharmacodynamic studies have been used to allow access to these drugs to patients with no further options because of economic constraints. In this study, we aimed to systematically review and assess evidence regarding the efficacy and safety of this adapted intervention.</p><p><strong>Methods: </strong>An expert librarian designed and conducted a literature search in MEDLINE, Scopus, Web of Science, EMBASE, Cochrane Central, and clinicaltrials.gov. Screening was conducted in a title/abstract and full-text phase independently and in duplicate. Primary outcomes were overall survival, overall response rates (ORRs), and incidence of adverse events (AEs). Data extraction was performed independently and in duplicate as well. A qualitative synthesis was performed and reported in the results.</p><p><strong>Results: </strong>Six studies investigated Nivo as an intervention, two Pembro, and 1 both therapies, with a total of 161 patients overall. One study had a single-arm prospective trial design and the rest a retrospective cohort design. ORR ranged from 66% to 100%, with complete response rates between 38% and 75%. The incidence of AEs was mostly high across all studies ranging from 27% to 93%, most of it composed of grade 1-2 AEs (27%-80%). No study reported health-related quality-of-life outcomes.</p><p><strong>Conclusion: </strong>Low-dose anti-PD1 immune checkpoint inhibitors have shown to be adequate candidates for testing of their efficacy in randomized trials and could improve access to these high-cost medications for patients with Hodgkin lymphoma both in LMICs and high-income countries.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400538"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confronting the Challenges of Hepatocellular Carcinoma in Sub-Saharan Africa: Opportunities for Progress.","authors":"Sulaiman Nanji, Peter Kingham, Olusegun Isaac Alatise","doi":"10.1200/GO-24-00645","DOIUrl":"https://doi.org/10.1200/GO-24-00645","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400645"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Challenges in Palliative Care: A Survey on ASCO Guideline Adherence Among Health Care Providers in Low- and Middle-Income Countries.","authors":"Cristiane Decat Bergerot, Enrique Soto-Perez-de-Celis, Chadane Thompson, Rushil Patel, Jafar Al-Mondhiry, Tingting Zhang, Nathasha Dhawan, Darcy Burbage, Joseph McCollom, Mazie Tsang, Ramy Sedhom, William E Rosa","doi":"10.1200/GO-24-00625","DOIUrl":"10.1200/GO-24-00625","url":null,"abstract":"<p><strong>Purpose: </strong>Integrating palliative care into oncology is essential, yet disparities in access and quality persist, particularly in low- and middle-income countries (LMICs). The ASCO guidelines advocate for early, routine, interdisciplinary palliative care for patients with advanced cancer. Barriers to implementing these recommendations include resource limitations, inadequate training, and cultural perceptions. Recognizing these challenges is essential for improving equitable access to palliative care worldwide.</p><p><strong>Methods: </strong>This prospective survey assessed adherence to ASCO recommendations for palliative care integration among LMIC health care providers (HCPs). Participants were recruited via e-mail, social media, and a list of members involved in the ASCO Palliative Care Communities of Practice from February to May 2024. The survey included sections on sociodemographic information, self-perceived adherence to ASCO guidelines on a 5-point Likert scale, and open-ended questions on implementation barriers. Data were collected using Research Electronic Data Capture system. Participants were grouped by WHO regions. Descriptive statistics were used to summarize characteristics and adherence scores, and chi-square tests were used to evaluate regional differences. Thematic analysis identified key themes from open-ended responses.</p><p><strong>Results: </strong>One hundred eighty HCPs participated; 62% was female, and 51.1% was age 35-44 years. Most were physicians (66%), and 50% lacked palliative care specialization. Adherence to ASCO guidelines varied, with early palliative care referrals ranging from 50% in the Americas region to 0% in the Western Pacific region. Key barriers included lack of policy support (25%), unmet educational needs (22%), and accessibility constraints (19%).</p><p><strong>Conclusion: </strong>Addressing identified barriers through evidence-based advocacy, comprehensive policy changes, training, and continuing education programs is essential for integrating palliative care into oncology services across LMICs, promoting health equity for patients with cancer.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400625"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and Opportunities in Head and Neck Cancer Research in Developing Countries: Insights From a Fireside Chat.","authors":"Aline Lauda Freitas Chaves, Luiz Paulo Kowalski, Gustavo Nader Marta, Alan Roger Santos-Silva, Luciana Vieira Muniz, Milena Perez Mak, Gustavo Gossling, Vítor Souza Guimaraes, Dalvaro Oliveira de Castro Junior, Thiago Bueno de Oliveira, Carmen Silvia Passos Lima, Ligia Traldi Macedo, Alexandre Arthur Jacinto, Guilherme Harada, Malu Viter da Rosa Barbosa, Izabella Costa Santos, Eronides Salustiano Batalha Filho, Gilberto De Castro Junior, Pedro Rafael Martins de Marchi, Leandro Luongo Matos, Maria Paula Curado, Hisham Mehanna, William Nassib William","doi":"10.1200/GO-25-00207","DOIUrl":"https://doi.org/10.1200/GO-25-00207","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in developing countries, where access to early diagnosis, comprehensive care, and research infrastructure is limited. This article synthesizes the insights generated during a Fireside Chat convened by members of the Latin American Cooperative Oncology Group (LACOG)-Head and Neck and the Brazilian Group of Head and Neck Cancer (GBCP), with the participation of international expert Professor Hisham Mehanna. The discussion addressed key challenges and opportunities in clinical and translational research within resource-constrained settings. Major themes included the unmet needs of patients with HNSCC, particularly regarding treatment-related toxicities and the need for biomarker-driven, personalized approaches. Barriers to research in low- and middle-income countries were explored, including patient comorbidities, late-stage presentation, and regulatory hurdles. The group emphasized the importance of pragmatic, context-sensitive research that reflects local disease burden, health care structures, and cultural factors. Capacity building, multidisciplinary teamwork, and integration of translational science into clinical care were highlighted as essential for advancing outcomes. The manuscript also outlines the preparedness of Brazilian centers for early-phase trials, strategies to enhance patient recruitment, and mechanisms to strengthen collaboration among researchers, governmental agencies, and industry. Successful models from LACOG and GBCP were presented to illustrate local leadership in advancing HNSCC research. Ultimately, the authors advocate for a coordinated national research agenda that positions Brazil and similar nations as meaningful contributors to the global head and neck cancer research landscape, fostering innovation while addressing the realities of under-represented populations.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500207"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of an Adapted Tool to Measure Health-Related Social Needs for the Prostate Cancer Population in Nigeria.","authors":"Musliu Adetola Tolani, Mudi Awaisu, Christian Agbo Agbo, Ayodeji Olawale Afolayan, Kabir Abdulkareem, Bernice Ofori, Sarah Sandlow, Dennis Li, Adam Murphy","doi":"10.1200/GO-24-00525","DOIUrl":"https://doi.org/10.1200/GO-24-00525","url":null,"abstract":"<p><strong>Purpose: </strong>The lack of culturally appropriate tools is a key obstacle to the identification of unmet social needs in the cancer population of Nigeria. To support sustainable strategies for social needs screening and intervention, this study aimed to develop and validate a health-related social needs screening tool for the prostate cancer population in Nigeria.</p><p><strong>Patients and methods: </strong>The study was performed in three stages at three Nigerian tertiary hospitals: (1) instrument adaptation using the Health Leads social needs screening toolkit as the primary framework, which involved domain specification and question item prioritization through three rounds of Delphi surveys among 15 health care workers, 15 patients with prostate cancer, and 15 caregivers; (2) face validation among 10 patients with prostate cancer through cognitive interviews for feedback on format, language clarity, ease of answering, comprehensiveness and applicability, and then member checking to review and approve question modifications; and (3) pilot testing for reliability analysis and readability assessment among 30 patients with prostate cancer. Descriptive and inferential statistics and qualitative analysis were performed.</p><p><strong>Results: </strong>During the first Delphi round, the highest three of the 10 top-ranking domains were financial resource strain (84%), sociodemographics (80%), and behavioral/mental health (80%). For single-question item prioritization, an agreement was reached in the employment, education, social isolation, and supports domains during the second round, and for the remaining domains during the third round. The format, clarity, ease of answering, and comprehensiveness of seven question items were modified, and two question items were substituted during face validation. The modified tool had a Cronbach's α of .67 and was considered appropriate for second-grade readers.</p><p><strong>Conclusion: </strong>To our knowledge, this study developed the first screening tool with acceptable internal validity and understandability to assess social needs in the prostate cancer population of Nigeria.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400525"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected Prostate Cancer Incidence in the Middle East by 2050: Socioeconomic Disparities and Future Implications.","authors":"James Parisi, Yetkin Tuac, Okan Argun, Garrett Kearney, Luke W Chen, Ozlem Aynaci, Nadeem Pervez, Layth Mula-Hussain, Jonathan E Leeman, Miranda B Lam, Mutlay Sayan","doi":"10.1200/GO-25-00098","DOIUrl":"https://doi.org/10.1200/GO-25-00098","url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation.</p><p><strong>Methods: </strong>Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney <i>U</i> test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators.</p><p><strong>Results: </strong>In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 <i>v</i> 1.50; <i>P</i> = .009). Higher income countries exhibited a greater percentage increase (<i>P</i> = .033), and the income level correlated positively with incidence trends (<i>r</i> = 59.6%; <i>P</i> = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline (<i>P</i> = .031).</p><p><strong>Conclusion: </strong>Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500098"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Distribution and Challenges of Long-Distance Travel for Patients With Breast Cancer at the Uganda Cancer Institute.","authors":"Naghib Bogere, Bridget Sharon Angucia, Eva Kababiito Nangobi, Joanne Kayaga, Margaret Okello Nyeko, Margaret Nanteza Okello, Edinus Mable Namusoke, Joanita Kuratex Mirembe, Immaculate Mbarusha, Ezra Anecho, Benjamin Mwesige, Nixon Niyonzima, Victoria Abaliwano Walusansa","doi":"10.1200/GO-24-00533","DOIUrl":"https://doi.org/10.1200/GO-24-00533","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a major public health concern in Uganda, with limited research on its spatial distribution. With the increasing burden of breast cancer in Uganda, ensuring equitable access to care is crucial. This study investigates the spatial distribution of breast cancer cases across Uganda and describes travel distances patients travel to reach the Uganda Cancer Institute (UCI), the national cancer treatment center. By analyzing geographic patterns and disparities in accessibility, this research aims to inform targeted interventions for improved patient outcomes and a more equitable health care system.</p><p><strong>Patients and methods: </strong>This retrospective study analyzed data from patients with breast cancer treated at UCI from 2009 to 2023. We geocoded patient addresses and calculated the travel distance from each residence to UCI. Spatial analysis was performed using Moran I statistic to assess clustering patterns in breast cancer distribution.</p><p><strong>Results: </strong>This study mapped the residences of 1,926 patients with breast cancer. Over half (54.7%) were concentrated in the Central region, with a median distance to the UCI of 11.2 km. By contrast, patients from the Northern region faced a median journey of 291 km, highlighting a significant disparity in proximity to care. Distinct clusters of patients were identified beyond the capital, Kampala, notably in Mbale (Eastern region) and several towns within the Northern region (Arua, Adjumani, Gulu, and Lira), suggesting potential localized factors influencing breast cancer incidence.</p><p><strong>Conclusion: </strong>This study highlights significant regional disparities in access to breast cancer care in Uganda, emphasizing the need for targeted interventions to improve health care access and reduce the burden of long-distance travel for patients in remote areas.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400533"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).","authors":"Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Pooja Gupta, Arpita Singh, Arvind Upadhyay, Lakhan Kashyap, Ankita Pal, Amit Kumar, Sambit S Nanda, Ashutosh Mukherji, Ankita Rungta Kapoor, Satyajit Pradhan, Aseem Mishra, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Neha Singh, Shreya Shukla, Satyendra Narayan Singh, Varun Shukla, M V Manikandan, Arvind Suresh, Shripad Banavali, Somnath Dey, Kunal Ranjan Vinayak, Praveen Lakshman, Lokendra Gupta, Pratibha Gavel, Bhavesh P Bandekar, Vijay Patil, Vanita Noronha, Kumar Prabhash","doi":"10.1200/GO-25-00032","DOIUrl":"10.1200/GO-25-00032","url":null,"abstract":"<p><strong>Purpose: </strong>Platinum-refractory advanced head and neck squamous cell carcinoma (HNSCC) has poor outcomes and limited treatment options, especially in resource-constrained settings. Triple oral metronomic chemotherapy (OMCT), involving low-dose continuous administration of chemotherapeutic agents, has shown promise in phase II studies but lacks evidence from randomized controlled trials. This study evaluated whether triple OMCT improves overall survival (OS) compared with chemotherapy of physician discretion (CPD).</p><p><strong>Patients and methods: </strong>In this phase III randomized open-label study, 214 patients with advanced HNSCC who had previous platinum-based chemotherapy were randomly assigned 1:1 to receive either triple OMCT (arm A) with erlotinib, celecoxib, and methotrexate, or CPD (arm B). The primary end point was OS, with secondary end points including progression-free survival (PFS), quality of life (QOL), and safety. Kaplan-Meier and log-rank tests were used for OS and PFS, and Cox-proportional hazard models estimated hazard ratios. QOL was evaluated using European Organisation for Research and Treatment of Cancer QLQ-C30 and FACT H&N.</p><p><strong>Results: </strong>Median OS was 5 months in arm A and 3.1 months in arm B (hazard ratio [HR], 0.63 [95% CI, 0.47 to 0.83]; <i>P</i> = .00011). Median PFS was 4.8 months in arm A and 2.7 months in arm B (HR, 0.67 [95% CI, 0.52 to 0.87]; <i>P</i> < .0001). Previous treatment was a significant prognostic factor for OS, while age, tumor site, and previous treatment were significant for PFS. Triple OMCT improved global health status, physical functions, fatigue, and insomnia. It was well tolerated, with fewer grade 3 or higher adverse events than CPD (28.0% <i>v</i> 39.3%, <i>P</i> = .03).</p><p><strong>Conclusion: </strong>Triple OMCT is an effective and safe treatment for advanced HNSCC after platinum-based chemotherapy.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500032"},"PeriodicalIF":3.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Evolution in Patient-Reported Outcomes in Indian Women With Breast Cancer: A Longitudinal Study.","authors":"Suman Ghosh, Tabassum Wadasadawala, Sanjay Mohanty, Rajiv Sarin, Vani Parmar, Sudeep Gupta","doi":"10.1200/GO-24-00507","DOIUrl":"https://doi.org/10.1200/GO-24-00507","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is the most common malignancy among women in India and globally. Given the high survivorship, understanding the evolution of health-related quality of life (HRQoL) is crucial, yet comprehensive longitudinal studies from India are lacking.</p><p><strong>Patients and methods: </strong>This prospective observational study included 500 patients with BC registered between June 2019 and March 2022. HRQoL was assessed at pretreatment, treatment completion, and 6-month follow-up using European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, EORTC-QLQ-BR-23, and EQ-5D-5L tools. A linear mixed-effects model analyzed HRQoL trajectories and predictors.</p><p><strong>Results: </strong>The median patient age was 46 years, with 60.8% presenting with locally advanced disease; all patients underwent multimodal therapy, comprising surgery (57% mastectomy), chemotherapy (95%), and radiotherapy (RT; 77%). Pretreatment global QoL scores were influenced by age (younger fared better, <i>P</i> = .003), stage (<i>P</i> = .027), and social displacement (<i>P</i> = .038). Longitudinal assessment revealed a small decline in global QoL (-2.1) and EQ-VAS (-1.9), along with meaningful improvements in social (+12.8), cognitive (+4.3), and role function (+7.3). Symptom burden significantly decreased, except for deterioration in body image (-7) and sexual enjoyment (-16). Younger patients had slower recovery in physical (<i>P</i> = .003) and social function (<i>P</i> = .05), while school education and financial independence positively influenced QoL variation. Social displacement affected trajectories of QoL (<i>P</i> = .017), role (<i>P</i> = .032), and social function (<i>P</i> = .024). Extent of surgery and RT did not affect overall HRQoL trends, although RT recipients reported more fatigue (<i>P</i> = .029).</p><p><strong>Conclusion: </strong>To our knowledge, this is the first longitudinal HRQoL study in Indian patients with BC, showing significant improvement in most functional domains at early survivorship. Sociodemographic factors, such as age, social displacement, education, and financial independence, rather than treatment modalities, were stronger predictors of HRQoL. Longer follow-up is needed for a more comprehensive assessment.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400507"},"PeriodicalIF":3.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}